Table 3. Paclitaxel cumulative dose, dose reduction and peripheral neuropathy.
| All patients (n=188) | AT arm (n=95) | ATX arm (n=93) | P valuea | |
|---|---|---|---|---|
| Median cumulative dose, mg m−2 (range) | 1409 (90–1709) | 1519 (120–1709) | 1351 (90–1534) | <0.001 |
| Median relative dose intensityb (range) | 0.94 (0.06–1.18) | 0.94 (0.07–1.18) | 0.94 (0.06–1.18) | 0.28 |
|
Peripheral neuropathy,
n
(%) | ||||
| Grade 1 | 68 (36.2) | 34 (35.8) | 34 (36.6) | |
| Grade 2 | 41 (21.8) | 18 (18.9) | 23 (24.7) | |
| Grade 3 | 17 (9.0) | 9 (9.5) | 8 (8.6) | |
| No peripheral neuropathy | 62 (33.0) | 34 (35.8) | 28 (30.1) | |
| Dose reduction, n (%) | 87 (46) | 42 (44) | 45 (48) | 0.57 |
a
P value from comparison between AT and ATX arm.
b
Relative dose intensity was calculated as the ratio between actual paclitaxel dose given in a time period (mg m−2 week−1) and planned dose during 24 weeks of paclitaxel-containing therapy considering no dose modification. Cases of progression or death within 24 weeks were included until the events. Patients taken off study due to toxicity were included until the end of planned paclitaxel-containing therapy.